

4. RESPONSE TO ANTI - HYPERTENSIVE DRUGS

No of variants analyzed: 151

No of gene markers evaluated: 96

Data validated on: 256237 individuals

No of studies evaluated /Supportive evidences (Publications): 243

Molecule Class	Good Response	Intermediate Response	Poor Response	Evidence not found
Calcium Channel Blockers	Amlodipine	Nifedipine	Verapamil	Felodipine, Nitrendipine, Diltiazem
ARBs	Losartan, Telmisartan	--	Irbesartan, Candesartan	Olmesartan
Vasodilator Drugs	Regadenoson	--	--	Bepridil
Loop Diuretics	--	Torsemide, Furosemide, Bumetanide	Furosemide+ Spironolactone	--
Thiazide Diuretics	--	Hydrochlorothiazide	Chlorthalidone	Indapamide
Potassium Sparing Diuretics	Amiloride, Spironolactone	--	--	Triamterene, Eplerenone
ACE Inhibitors	Enalapril	Benazepril , Imidapril	Quinapril	Fosinopril, Ramipril
Beta Blockers	Bucindolol	Propranolol, Carvedilol, Atenolol, Metoprolol	Timolol	Esmolol, Pindolol, Nadolol

This Report is Confidential and belongs to:

Ghost Y

5. RESPONSE TO DIABETIC DRUGS

No of variants analyzed: 60

No of gene markers evaluated: 37

Data validated on: 39284 individuals

No of studies evaluated /Supportive evidences (Publications): 89

Molecule Class	Good Response	Intermediate Response	Poor Response	Evidence not found
Biguanides	Metformin	--	--	--
Sulfonylureas	--	--	Gliclazides, Glibenclamide, Glimepiride, Glipizide, Gliquidone	Glyburide Chlorpropamide Tolazamide Tolbutamide
GLP-1 receptor agonists	--	Liraglutide	--	Exenatide Liraglutide Lixisenatide Dulaglutide Albiglutide Semaglutide
Thiazolidinedione	Rosiglitazone	--	Pioglitazone	--
Glinides	--	Repaglinide	--	Nateglinide
SGLT-2 inhibitors	--	--	--	Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin
DPP4 Inhibitors	--	--	--	Linagliptin, Saxagliptin
Alpha - glucosidase inhibitors	--	--	--	Voglibose, Acarbose, Miglitol

This Report is Confidential and belongs to:

Ghost Y